Market Newsdesk

SAN DIEGO, July 24, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AeroVironment, Inc. (NASDAQ: AVAV) securities between June 25, 2025 and March 10, 2026, all dates inclusive (the “Class Period”), have until this upcoming Monday, July 27, 2026 to seek appointment as lead plaintiff of the AeroVironment class action lawsuit. Captioned Norrell v. AeroVironment, Inc., No. 26-cv-01429 (E.D. Va.), the AeroVironment class action lawsuit charges AeroVironment as well as certain of AeroVironment’s current and former executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

AeroVironment

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-aerovironment-class-action-lawsuit-avav.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: AeroVironment designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses. The AeroVironment class action lawsuit alleges on May 1, 2025, AeroVironment announced it had completed the acquisition of BlueHalo, LLC, which had previously been awarded a contract to support the U.S. Space Force’s Satellite Communication Augmentation Resource (“SCAR”) program. The SCAR program represents the U.S. Space Force’s efforts to modernize antennas used by the Satellite Control Network (“SCN”), which is comprised of 19 fixed antennas across the world and executes tasks such as tracking satellites, transmitting signals, and conducting telemetry, or accessing data from satellites to assess their status and health, according to the complaint.

The AeroVironment class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the SCAR program and the U.S. Space Force’s ongoing efforts to modernize the SCN; and (ii) accordingly, defendants overstated AeroVironment’s business and financial prospects.

The AeroVironment class action lawsuit further alleges that on January 20, 2026, AeroVironment announced that the U.S. government had issued a stop work order on AeroVironment’s agreement to deliver BADGER systems to the SCAR program. In the same announcement, AeroVironment allegedly stated that the stop work order “allows for the parties to negotiate an amended agreement for the future of the SCAR program” and that “[t]he Company expects to continue to deliver capabilities and products for the SCAR program.” On this news, the price of AeroVironment stock fell nearly 16%, according to the complaint.

Then, on March 2, 2026, SpaceNews allegedly reported that the U.S. Space Force was reopening the SCAR program and “reassessing how to move forward.” Space News quoted Colonel Owen Stevens, director of contracting at the Space Rapid Capabilities Office, which supervised SCAR, as stating: “We have been in conversations with the SAE [senior acquisition executive] for a little while now, and we are going to move into a new acquisition strategy for SCAR,” the complaint alleges. On this news, the price of AeroVironment stock fell more than 17%, according to the complaint.

Finally, on March 10, 2026, the complaint alleges that AeroVironment announced its financial results for the third quarter of fiscal year 2026. Among other items, AeroVironment allegedly reported a third-quarter operating loss of $179.0 million, compared to an operating loss of $3.1 million for the same period in fiscal year 2025. These financial results reflected the impact of a $151.3 million goodwill impairment in AeroVironment’s space division after the stop work order on AeroVironment’s BADGER systems built for the SCAR program, according to the AeroVironment class action lawsuit. AeroVironment also allegedly reported that the U.S. Space Force had terminated AeroVironment’s contract concerning the SCAR program, and as a result, it would have to “recompete” for the SCAR program. On this news, the price of AeroVironment stock fell more than 6%, the complaint alleges.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired AeroVironment securities during the Class Period to seek appointment as lead plaintiff in the AeroVironment class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the AeroVironment class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the AeroVironment class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the AeroVironment class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

Conference Call Scheduled for 8:30 a.m. Eastern Time

JUPITER, Fla, July 24, 2026 (GLOBE NEWSWIRE) — AMG (NYSE: AMG) will report financial and operating results for the second quarter and six months ended June 30, 2026 on Thursday, July 30, 2026. A conference call will be held at 8:30 a.m. Eastern time on the same day.
        
In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, and Dava E. Ritchea, Chief Financial Officer, will host the session.

Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins.

The conference call will also be available for replay beginning approximately one hour after the conclusion of the call. To hear a replay of the call, please dial 1-877-660-6853 (U.S. calls) or 1-201-612-7415 (non-U.S. calls) and provide conference ID 13761085. The live call and replay of the session, and a presentation highlighting the Company’s performance, can also be accessed via AMG’s website at https://ir.amg.com/.

For more information on AMG, please visit www.amg.com.

© 2026 Affiliated Managers Group, Inc. All rights reserved.

Investor & Media Relations:
Patricia Figueroa
+1 (617) 747-3300
[email protected]
[email protected]

ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at NovaBridge Biosciences Shanghai office, 38F, AIA Tower, No. 866 Dongchangzhi Road, Shanghai, China on September 8, 2026 at 10:00 a.m. (Shanghai time).

Holders of record of ordinary shares of a par value of US$0.0001 each of the Company at the close of business on July 27, 2026 (Shanghai time) are entitled to notice of, to attend and to vote at, the AGM or any adjournment(s) or postponement(s) thereof. Holders of the Company’s American depositary shares (“ADSs”) as of the close of business on July 27, 2026 (New York time) who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company’s ADSs, Citibank, N.A.

The Notice of AGM, which sets forth the resolution to be submitted to shareholder approval at the AGM, and the form of proxy for the AGM are available on the Company’s website at https://www.novabridge.com.

The Company has filed its annual report on Form 20-F (as amended by Amendment No. 1 to the annual report on Form 20-F, the “Annual Report”), including its audited financial statements, for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). The Annual Report can be accessed on the Company’s website at https://www.novabridge.com, as well as on the SEC’s website at https://www.sec.gov.

About NovaBridge Biosciences

NovaBridge is a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets, enabling transformative therapies to progress rapidly from discovery toward patients in need.

The Company’s differentiated pipeline is led by givastomig, a potential first-in-class Claudin 18.2-Targeted Immuno Amplifier (CTIA) — a Claudin 18.2 × 4-1BB bispecific antibody — and VIS-101, a purpose-designed, potential best-in-class dual VEGF-A × ANG-2 inhibitor.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed, and is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. It is being evaluated in a global, randomized Phase 2 study, following positive topline results from a Phase 1b, multicenter, open-label study in first-line gastric cancer. NovaBridge is also collaborating with its partner, ABL Bio, on ragistomig, a bispecific antibody combining PD-L1 as a tumor engager with 4-1BB as a conditional T-cell activator, in solid tumors. In addition, NovaBridge holds worldwide rights outside of China to uliledlimab, an anti-CD73 antibody targeting adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more rapid, robust, and durable treatment responses for patients with retinal vascular diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. It has completed a randomized, dose-ranging Phase 2a study in wet AMD and expects to initiate a dose-determining Phase 2b study in the second half of 2026. NovaBridge is the majority shareholder of Visara, Inc., which controls global rights to VIS-101 outside of Greater China and certain countries in Asia.

For more information, visit http://www.novabridge.com and follow NovaBridge on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “believes,” “designed to,” “anticipates,” “future,” “intends,” “plans,” “potential,” “estimates,” “confident,” “look forward” and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations regarding the AGM; the strategic and clinical development of the Company’s drug candidates, including givastomig, VIS-101, ragistomig, and uliledlimab; the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for these product candidates; and anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval or eligibility for or achievement of Accelerated Approval Pathway; the content and timing of decisions made by the relevant regulatory authorities, including the FDA, regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 7, 2026 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

NovaBridge Investor & Media Contacts

NovaBridge Biosciences        
+1-240-745-6330
[email protected]

Bill Begien, VP, Investor Relations        
[email protected]

Jessica Zhang, Director, Public Relations        
[email protected]

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026.

The date of the 2026 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2025 Annual Meeting. Given the adjustment, stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must be received in writing by the Company before the close of business on August 3, 2026 to be considered for inclusion in the Company’s proxy materials for the 2026 Annual Meeting.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at https://pelthos.com/. Follow Pelthos on LinkedIn and X.

Contacts

Investors:

LifeSci Advisors, LLC
Mike Moyer, Managing Director
[email protected]

Media:

KWM Communications
Kellie Walsh
[email protected]
(914) 315-6072

Mdxhealth Announces Receipt of Nasdaq Notification Regarding
Minimum Market Value of Listed Securities Deficiency

IRVINE, California – July 24, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leader in urology-focused precision diagnostics, today announced that the Company received an additional notification letter (the “Additional Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) related to the recent reduction in the price for the Company’s ordinary shares. The initial notice, reported by the Company in its Form 6-K filed on July 2, 2026, related to the Company’s non-compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing. The Supplemental Letter, received on July 20, 2026, notifies the Company that it is not in compliance with the minimum market value requirement set forth in rules for continued listing on The Nasdaq Capital Market.

Nasdaq Listing Rule 5550(b)(2) requires listed companies to maintain a minimum market value of US$35 million and Nasdaq Listing Rule 5810(c)(3)(C) provides that a failure to meet the minimum market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company from June 1, 2026, to July 17, 2026, the Company no longer meets the minimum market value requirement.

The Additional Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided 180 calendar days, or until January 19, 2027, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance, the Company’s market value must exceed US$35 million for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 19, 2027, the Company may be eligible for additional time to regain compliance or may face delisting. In the event of such a notification, the Nasdaq rules permit the Company an opportunity to appeal Nasdaq’s determination.

The Company’s business operations are not affected by the receipt of the Additional Letter. The Company intends to monitor its market value and intends to cure the deficiency within the prescribed grace period.

About mdxhealth

Mdxhealth is a leader in urology-focused precision diagnostics, providing actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: x.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

[email protected]

LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
[email protected]

Forward-Looking Statement:

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding our intent to monitor our Market Value of Listed Securities and to consider options to regain compliance with the minimum Market Value of Listed Securities requirement under the Nasdaq Listing Rules. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to cure any deficiencies in compliance with the Market Value of Listed Securities requirement or maintain compliance with other Nasdaq Listing Rules; our eligibility for additional compliance periods, if necessary, in which to seek to regain compliance with the Market Value of Listed Securities requirement; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or to meet applicable Nasdaq requirements for any such relief or extension; and risks related to the substantial costs and diversion of personnel’s attention and resources due to these matters. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE:

The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, GPS, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS mdx test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.

Attachment

• MDXH

CORYDON, Ind., July 24, 2026 (GLOBE NEWSWIRE) — First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $4.8 million, or $1.43 per diluted share, for the quarter ended June 30, 2026, compared to net income of $3.8 million, or $1.13 per diluted share, for the quarter ended June 30, 2025.

Results of Operations for the Three Months Ended June 30, 2026 and 2025

Net interest income after provision for credit losses increased $1.6 million for the quarter ended June 30, 2026 compared to the same period in 2025. Interest income increased $1.6 million when comparing the two periods due to an increase in the average tax-equivalent yield⁽¹⁾ on interest-earning assets from 4.82% for the second quarter of 2025 to 5.12% for the same period in 2026, in addition to an increase in the average balance of interest-earning assets from $1.18 billion for the second quarter of 2025 to $1.24 billion for the same period in 2026. Interest expense decreased $93,000 when comparing the periods as the average cost of interest-bearing liabilities decreased from 1.64% for the quarter ended June 30, 2025 to 1.56% for the same period in 2026 while the average balance of interest-bearing liabilities increased from $883.8 million for the quarter ended June 30, 2025 to $907.3 million for the same period in 2026. As a result of the changes in interest-earning assets and interest-bearing liabilities, the tax-equivalent net interest margin⁽¹⁾ increased from 3.59% for the quarter ended June 30, 2025 to 3.98% for the same period in 2026. Refer to the accompanying average balance sheet for more information regarding changes in the composition of the Company’s balance sheet and resulting yields and costs from the quarter ended June 30, 2025 to the quarter ended June 30, 2026.

Based on management’s analysis of the Allowance for Credit Losses (“ACL”) on loans and unfunded loan commitments, the provision for credit losses increased from $306,000 for the quarter ended June 30, 2025 to $425,000 for the quarter ended June 30, 2026.   The Bank recognized net charge-offs of $58,000 and $113,000 for the quarters ended June 30, 2026 and 2025, respectively.

Noninterest income increased $187,000 for the quarter ended June 30, 2026 as compared to the quarter ended June 30, 2025. The increase is primarily due to the Company recognizing a $92,000 gain on equity securities during the quarter ended June 30, 2026 compared to a loss of $41,000 during the same period in 2025. In addition, the Company recognized an increase of $54,000 in service charges on deposit accounts when comparing the two periods.

Noninterest expenses increased $359,000 for the quarter ended June 30, 2026 as compared to the same period in 2025. This was primarily due to increases in compensation and benefits, advertising, and other expenses of $235,000, $84,000 and $79,000, respectively, when comparing the two periods.   The increase in compensation and benefits is due to increases in salary and wages associated with annual cost of living and performance related adjustments as well as increases in the cost of Company-provided health insurance benefits. The increase in advertising expenses is related to various new marketing campaigns undertaken during the quarter ended June 30, 2026. The increase in other expenses was primarily due to general inflationary pressures and routine pricing increases rather than any specific item. These increases were partially offset by a $75,000 decrease in professional services when comparing the two periods due to fewer consulting fees during the quarter ended June 30, 2026.  

Income tax expense increased $397,000 for the quarter ended June 30, 2026 as compared to the same period in 2025 resulting in an effective tax rate of 20.8% for the quarter ended June 30, 2026, compared to 18.4% for the same period in 2025. The increase in the Company’s effective tax rate for the quarter ended June 30, 2026 reflects a higher proportion of net income being subject to taxation compared to the same period last year.

Results of Operations for the Six Months Ended June 30, 2026 and 2025

For the six months ended June 30, 2026, the Company reported net income of $9.1 million, or $2.72 per diluted share, compared to net income of $7.0 million, or $2.09 per diluted share, for the same period in 2025.

Net interest income after provision for credit losses increased $3.4 million for the six months ended June 30, 2026 compared to the same period in 2025. Interest income increased $3.2 million when comparing the two periods due to an increase in the average tax-equivalent yield⁽¹⁾ on interest-earning assets from 4.73% for the six months ended June 30, 2025 to 5.04% for the same period in 2026, in addition to an increase in the average balance of interest-earning assets from $1.18 billion for the six months ended June 30, 2025 to $1.23 billion for the same period in 2026. Interest expense decreased $352,000 when comparing the periods as the average cost of interest-bearing liabilities decreased from 1.67% for the six months ended June 30, 2025 to 1.56% for the same period in 2026 while the average balance of interest-bearing liabilities increased from $883.2 million for the six months ended June 30, 2025 to $904.4 million for the same period in 2026. As a result of the changes in interest-earning assets and interest-bearing liabilities, the tax-equivalent net interest margin⁽¹⁾ increased from 3.47% for the six months ended June 30, 2025 to 3.90% for the same period in 2026. Refer to the accompanying average balance sheet for more information regarding changes in the composition of the Company’s balance sheet and resulting yields and costs from the six months ended June 30, 2025 to the six months ended June 30, 2026.

Based on management’s analysis of the ACL on loans and unfunded loan commitments, the provision for credit losses increased from $644,000 for the six months ended June 30, 2025 to $775,000 for the six months ended June 30, 2026. The Bank recognized net charge-offs of $169,000 and $197,000 for the six months ended June 30, 2026 and 2025, respectively.

Noninterest income increased $387,000 for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025. The increase is primarily due to the Company recognizing a $270,000 gain on equity securities during the six months ended June 30, 2026 compared to a loss of $23,000 during the same period in 2025. In addition, the Company recognized increases of $70,000 and $53,000 in ATM and debit card fee income and service charges on deposit accounts, respectively, when comparing the two periods. These increases were partially offset by the Company recognizing a $92,000 loss on sale of available for sale securities for the six months ended June 30, 2026 compared to a loss of $55,000 for the same period in 2025. The loss on sale of available for sale securities during the six months ended June 30, 2026 was a result of management’s decision to sell $18.7 million of available for sale securities to better position the Company’s investment portfolio for increased future yields.

Noninterest expenses increased $931,000 for the six months ended June 30, 2026 as compared to the same period in 2025. This was primarily due to increases in compensation and benefits, other expenses, professional services, and advertising expenses of $470,000, $178,000, $166,000 and $82,000, respectively, when comparing the two periods. The increase in compensation and benefits is due to increases in salary and wages associated with annual cost of living and performance related adjustments as well as increases in the cost of Company-provided health insurance benefits. The increase in other expenses is primarily due to an increase in consumer fraud losses and increased support of the Company’s local communities through sponsorships and donations during the six months ended June 30, 2026 as compared to the same period in 2025.   The increase in professional services is due to increased consulting fees. The increase in advertising expenses is related to various new marketing campaigns undertaken during the six months ended June 30, 2026 as compared to the same period in 2025.

Income tax expense increased $755,000 for the six months ended June 30, 2026 as compared to the same period in 2025 resulting in an effective tax rate of 20.0% for the six months ended June 30, 2026, compared to 17.9% for the same period in 2025. The increase in the Company’s effective tax rate for the six months ended June 30, 2026 reflects a higher proportion of net income being subject to taxation compared to the same period last year.

Comparison of Financial Condition at June 30, 2026 and December 31, 2025

Total assets were $1.29 billion at June 30, 2026 compared to $1.27 billion at December 31, 2025. Net loans receivable and cash and cash equivalents increased $14.0 million and $12.5 million, respectively, from December 31, 2025 to June 30, 2026. These increases were partially offset by a decrease of $10.3 million in available for sale securities when comparing the two periods. Deposits increased $13.7 million from $1.12 billion at December 31, 2025 to $1.14 billion at June 30, 2026. Nonperforming assets (consisting of nonaccrual loans, accruing loans 90 days or more past due, and foreclosed real estate) increased from $4.4 million at December 31, 2025 to $4.9 million at June 30, 2026.

The Bank currently has 17 offices in the Indiana communities of Corydon, Edwardsville, Greenville, Floyds Knobs, Palmyra, New Albany, New Salisbury, Jeffersonville, Salem, Lanesville and Charlestown and the Kentucky communities of Shepherdsville, Mt. Washington and Lebanon Junction.

Access to First Harrison Bank accounts, including online banking and electronic bill payments, is available through the Bank’s website at www.firstharrison.com. For more information and financial data about the Company, please visit Investor Relations at the Bank’s aforementioned website. The Bank can also be followed on Facebook.

(1) Reconciliations of the non–U.S. Generally Accepted Accounting Principles (“GAAP”) measures are set forth at the end of this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of the words “anticipate,” “believe,” “expect,” “intend,” “could” and “should,” and other words of similar meaning. Forward-looking statements are not historical facts nor guarantees of future performance; rather, they are statements based on the Company’s current beliefs, assumptions, and expectations regarding its business strategies and their intended results and its future performance.

Numerous risks and uncertainties could cause or contribute to the Company’s actual results, performance and achievements to be materially different from those expressed or implied by these forward-looking statements. Factors that may cause or contribute to these differences include, without limitation, general economic conditions, including changes in market interest rates and changes in monetary and fiscal policies of the federal government; competition; the ability of the Company to execute its business plan; legislative and regulatory changes; the quality and composition of the loan and investment portfolios; loan demand; deposit flows; changes in accounting principles and guidelines; and other factors disclosed periodically in the Company’s filings with the Securities and Exchange Commission.

Because of the risks and uncertainties inherent in forward-looking statements, readers are cautioned not to place undue reliance on them, whether included in this press release, the Company’s reports, or made elsewhere from time to time by the Company or on its behalf. These forward-looking statements are made only as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements after the date of this press release.

Contact:

Joshua P. Stevens
Chief Financial Officer
812-738-1570

FIRST CAPITAL, INC. AND SUBSIDIARIES Consolidated Financial Highlights (Unaudited)
	Three Months Ended								Six Months Ended
	June 30,								June 30,
OPERATING DATA	2026				2025				2026				2025
(Dollars in thousands, except per share data)
Total interest income	$	15,622			$	14,040			$	30,546			$	27,386
Total interest expense		3,535				3,628				7,041				7,393
Net interest income		12,087				10,412				23,505				19,993
Provision for credit losses		425				306				775				644
Net interest income after provision for credit losses		11,662				10,106				22,730				19,349
Total non-interest income		2,205				2,018				4,253				3,866
Total non-interest expense		7,853				7,494				15,606				14,675
Income before income taxes		6,014				4,630				11,377				8,540
Income tax expense		1,249				852				2,279				1,524
Net income		4,765				3,778				9,098				7,016
Less net income attributable to the noncontrolling interest		3				3				6				6
Net income attributable to First Capital, Inc.	$	4,762			$	3,775			$	9,092			$	7,010
Net income per share attributable to
First Capital, Inc. common shareholders:
Basic	$	1.43			$	1.13			$	2.73			$	2.09
Diluted	$	1.43			$	1.13			$	2.72			$	2.09
Weighted average common shares outstanding:
Basic		3,336,190				3,346,653				3,336,134				3,346,751
Diluted		3,339,690				3,350,344				3,339,124				3,349,308
OTHER FINANCIAL DATA
Cash dividends per share	$	0.31			$	0.29			$	0.62			$	0.58
Return on average assets (annualized)		1.49	%			1.24	%			1.43	%			1.16	%
Return on average equity (annualized)		13.60	%			12.59	%			12.98	%			11.86	%
Net interest margin		3.91	%			3.52	%			3.82	%			3.40	%
Net interest margin (tax-equivalent basis) (1)		3.98	%			3.59	%			3.90	%			3.47	%
Interest rate spread		3.49	%			3.11	%			3.41	%			2.99	%
Interest rate spread (tax-equivalent basis) (1)		3.56	%			3.18	%			3.48	%			3.06	%
Net overhead expense as a percentage of average assets (annualized)		2.46	%			2.47	%			2.45	%			2.43	%

	June 30,				December 31,
BALANCE SHEET INFORMATION	2026				2025
Cash and cash equivalents	$	149,812			$	137,288
Interest-bearing time deposits		1,225				1,470
Investment securities		413,917				424,190
Gross loans		678,838				664,208
Allowance for credit losses		10,714				10,108
Earning assets		1,215,369				1,193,475
Total assets		1,290,041				1,271,995
Deposits		1,136,731				1,122,990
Stockholders’ equity, net of noncontrolling interest		142,510				137,797
Allowance for credit losses as a percentage of gross loans		1.58	%			1.52	%
Non-performing assets:
Nonaccrual loans		4,920				4,268
Accruing loans past due 90 days		—				83
Foreclosed real estate		—				—
Regulatory capital ratios (Bank only):
Community Bank Leverage Ratio (2)		11.34	%			11.01	%

______________________________

(1)  See reconciliation of GAAP and non-GAAP financial measures for additional information relating to the calculation of this item.
(2)  Effective March 31, 2020, the Bank opted in to the Community Bank Leverage Ratio (CBLR) framework. As such, the other regulatory ratios are no longer provided.

FIRST CAPITAL, INC. AND SUBSIDIARIES Consolidated Average Balance Sheets (Unaudited)
	For the Three Months ended June 30,
	2026										2025
								Average										Average
	Average							Yield/			Average							Yield/
	Balance			Interest				Cost			Balance			Interest				Cost
(Dollars in thousands)
Interest earning assets:
Loans (1) (2):
Taxable	$	661,948		$	10,675			6.45	%		$	643,824		$	10,165			6.32	%
Tax-exempt (3)		12,774			176			5.51	%			10,686			114			4.27	%
Total loans		674,722			10,851			6.43	%			654,510			10,279			6.28	%
Investment securities:
Taxable (4)		312,690			2,889			3.70	%			308,527			2,004			2.60	%
Tax-exempt (3)		119,056			902			3.03	%			118,418			842			2.84	%
Total investment securities		431,746			3,791			3.51	%			426,945			2,846			2.67	%
Interest bearing deposits with banks (5)		130,539			1,207			3.70	%			100,563			1,116			4.44	%
Total interest earning assets		1,237,007			15,849			5.12	%			1,182,018			14,241			4.82	%
Non-interest earning assets		42,055										34,037
Total assets	$	1,279,062									$	1,216,055
Interest bearing liabilities:
Interest-bearing demand deposits	$	442,178		$	1,203			1.09	%		$	440,186		$	1,334			1.21	%
Savings accounts		223,630			100			0.18	%			228,261			165			0.29	%
Time deposits		241,466			2,232			3.70	%			215,314			2,129			3.96	%
Total deposits		907,274			3,535			1.56	%			883,761			3,628			1.64	%
Total interest bearing liabilities		907,274			3,535			1.56	%			883,761			3,628			1.64	%
Non-interest bearing liabilities
Non-interest bearing deposits		219,031										202,365
Other liabilities		12,664										9,965
Total liabilities		1,138,969										1,096,091
Stockholders’ equity (6)		140,093										119,964
Total liabilities and stockholders’ equity	$	1,279,062									$	1,216,055
Net interest income (tax-equivalent basis)				$	12,314									$	10,613
Less: tax equivalent adjustment					(227	)									(201	)
Net interest income				$	12,087									$	10,412
Interest rate spread								3.49	%									3.11	%
Interest rate spread (tax-equivalent basis) (7)								3.56	%									3.18	%
Net interest margin								3.91	%									3.52	%
Net interest margin (tax-equivalent basis) (7)								3.98	%									3.59	%
Ratio of average interest earning assets to average interest bearing liabilities								136.34	%									133.75	%

______________________________

(1)  Interest income on loans includes fee income of $227,000 and $222,000 for the three months ended June 30, 2026 and 2025, respectively.
(2)  Average loan balances include loans held for sale and nonperforming loans.
(3)  Tax-exempt income has been adjusted to a tax-equivalent basis using the federal marginal tax rate of 21%.
(4)  Includes taxable debt and equity securities and FHLB Stock.
(5)  Includes interest-bearing deposits with banks and interest-bearing time deposits.
(6)  Stockholders’ equity attributable to First Capital, Inc.
(7)  Reconciliations of the non–U.S. GAAP measures are set forth at the end of this press release.

FIRST CAPITAL, INC. AND SUBSIDIARIES Consolidated Average Balance Sheets (Unaudited)
	For the Six Months ended June 30,
	2026										2025
								Average										Average
	Average							Yield/			Average							Yield/
	Balance			Interest				Cost			Balance			Interest				Cost
(Dollars in thousands)
Interest earning assets:
Loans (1) (2):
Taxable	$	660,861		$	21,030			6.36	%		$	638,326		$	19,849			6.22	%
Tax-exempt (3)		11,517			285			4.95	%			10,786			228			4.23	%
Total loans		672,378			21,315			6.34	%			649,112			20,077			6.19	%
Investment securities:
Taxable (4)		315,200			5,626			3.57	%			309,248			3,864			2.50	%
Tax-exempt (3)		119,093			1,792			3.01	%			118,650			1,663			2.80	%
Total investment securities		434,293			7,418			3.42	%			427,898			5,527			2.58	%
Interest bearing deposits with banks (5)		122,624			2,249			3.67	%			98,723			2,179			4.41	%
Total interest earning assets		1,229,295			30,982			5.04	%			1,175,733			27,783			4.73	%
Non-interest earning assets		43,940										31,697
Total assets	$	1,273,235									$	1,207,430
Interest bearing liabilities:
Interest-bearing demand deposits	$	439,812		$	2,367			1.08	%		$	439,952		$	2,743			1.25	%
Savings accounts		223,502			199			0.18	%			226,842			328			0.29	%
Time deposits		241,060			4,475			3.71	%			216,418			4,322			3.99	%
Total deposits		904,374			7,041			1.56	%			883,212			7,393			1.67	%
Total interest bearing liabilities		904,374			7,041			1.56	%			883,212			7,393			1.67	%
Non-interest bearing liabilities
Non-interest bearing deposits		216,123										198,218
Other liabilities		12,603										7,804
Total liabilities		1,133,100										1,089,234
Stockholders’ equity (6)		140,135										118,196
Total liabilities and stockholders’ equity	$	1,273,235									$	1,207,430
Net interest income (tax-equivalent basis)				$	23,941									$	20,390
Less: tax equivalent adjustment					(436	)									(397	)
Net interest income				$	23,505									$	19,993
Interest rate spread								3.41	%									2.99	%
Interest rate spread (tax-equivalent basis) (7)								3.48	%									3.06	%
Net interest margin								3.82	%									3.40	%
Net interest margin (tax-equivalent basis) (7)								3.90	%									3.47	%
Ratio of average interest earning assets to average interest bearing liabilities								135.93	%									133.12	%

______________________________

(1)  Interest income on loans includes fee income of $419,000 and $358,000 for the six months ended June 30, 2026 and 2025, respectively.
(2)  Average loan balances include loans held for sale and nonperforming loans.
(3)  Tax-exempt income has been adjusted to a tax-equivalent basis using the federal marginal tax rate of 21%.
(4)  Includes taxable debt and equity securities and FHLB Stock.
(5)  Includes interest-bearing deposits with banks and interest-bearing time deposits.
(6)  Stockholders’ equity attributable to First Capital, Inc.
(7)  Reconciliations of the non–U.S. GAAP measures are set forth at the end of this press release.

RECONCILIATION OF GAAP AND NON-GAAP FINANCIAL MEASURES (UNAUDITED):

This presentation contains financial information determined by methods other than in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Management uses these “non-GAAP” measures in its analysis of the Company’s performance. Management believes that these non-GAAP financial measures allow for better comparability with prior periods, as well as with peers in the industry who provide a similar presentation, and provide a further understanding of the Company’s ongoing operations. These disclosures should not be viewed as a substitute for operating results determined in accordance with GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. The following table summarizes the non-GAAP financial measures derived from amounts reported in the Company’s consolidated financial statements and reconciles those non-GAAP financial measures with the comparable GAAP financial measures.

	Three Months Ended								Six Months Ended
	June 30,								June 30,
	2026				2025				2026				2025
(Dollars in thousands)
Net interest income (A)	$	12,087			$	10,412			$	23,505			$	19,993
Add: Tax-equivalent adjustment		227				201				436				397
Tax-equivalent net interest income (B)		12,314				10,613				23,941				20,390
Average interest earning assets (C)		1,237,007				1,182,018				1,229,295				1,175,733
Net interest margin (A)/(C)		3.91	%			3.52	%			3.82	%			3.40	%
Net interest margin (tax-equivalent basis) (B)/(C)		3.98	%			3.59	%			3.90	%			3.47	%
Total interest income (D)	$	15,622			$	14,040			$	30,546			$	27,386
Add: Tax-equivalent adjustment		227				201				436				397
Total interest income tax-equivalent basis (E)		15,849				14,241				30,982				27,783
Average interest earning assets (F)		1,237,007				1,182,018				1,229,295				1,175,733
Average yield on interest earning assets (D)/(F); (G)		5.05	%			4.75	%			4.97	%			4.66	%
Average yield on interest earning assets tax-equivalent (E)/(F); (H)		5.12	%			4.82	%			5.04	%			4.73	%
Average cost of interest bearing liabilities (I)		1.56	%			1.64	%			1.56	%			1.67	%
Interest rate spread (G)-(I)		3.49	%			3.11	%			3.41	%			2.99	%
Interest rate spread tax-equivalent (H)-(I)		3.56	%			3.18	%			3.48	%			3.06	%

HAVERTOWN, Pa., July 24, 2026 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $10,288,000, or $1.91 per diluted share, for its 2026 fiscal year ended April 30, 2026 compared to net income of $12,716,000, or $2.37 per diluted share, for the same period of the prior year. Revenues were $52,847,000 for fiscal 2026 and $49,694,000 for fiscal 2025.

More information about the Company’s financial performance in 2026 and 2025 may be found in AMREP Corporation’s financial statements on Form 10-K which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (www.amrepcorp.com/sec-filings/). As a result of many factors, including the nature and timing of specific transactions and the type and location of land or homes being sold, revenues, average selling prices and related gross margins from land sales or home sales can vary significantly from period to period and prior results are not necessarily a good indication of what may occur in future periods.

AMREP Corporation, through its subsidiaries, is a major holder of land, leading developer of real estate and award-winning homebuilder in New Mexico.

FINANCIAL HIGHLIGHTS
		Twelve Months Ended April 30,
		2026			2025
Revenues		$	52,847,000		$	49,694,000
Net income		$	10,288,000		$	12,716,000
Income per share – basic		$	1.93		$	2.39
Income per share – diluted		$	1.91		$	2.37
Weighted average number of common shares outstanding – basic			5,337,000			5,318,000
Weighted average number of common shares outstanding – diluted			5,393,000			5,369,000

CONTACT:
Adrienne M. Uleau
Chief Financial Officer and Vice President
(610) 487-0907

BROOMFIELD, Colo., July 24, 2026 (GLOBE NEWSWIRE) — Gogo Inc. (NASDAQ: GOGO), the leading global provider of broadband connectivity services for the business aviation, military, and government markets, announced today that it will release its second quarter 2026 financial results before the market opens on August 6, 2026. The Company will host a conference call with financial analysts on the same day at 8:30 a.m. (ET).

Conference call & webcast

A webcast of the conference call and a replay will be available online on the Investor Relations section of the Company’s investor website at https://ir.gogoair.com/

Gogo 2Q 2026 Earnings Call – participants can join the webcast through this link
https://edge.media-server.com/mmc/p/czisjqz9

Participants can use the link below to retrieve a unique conference ID to access the conference call.
https://register-conf.media-server.com/register/BIc1371241a7b64561b1ebf76042a13f3b

About Gogo

Gogo is the only multi-orbit, multi-band in-flight connectivity provider offering connectivity technology purpose-built for business and military/government aviation. Its industry-leading product portfolio offers best-in-class solutions for all aircraft types, from small to large and heavy jets and beyond.

The Gogo offering uniquely incorporates air-to-ground systems with access to high-speed satellite networks, which aim to deliver consistent, global tip-to-tail connectivity through a sophisticated suite of software, hardware, and advanced infrastructure supported by a 24/7/365 in-person customer support team.

Gogo consistently strives to set new standards for reliability, security, and innovation and is shaping the future of inflight aviation to make it easier for every customer to stay connected beyond all expectations.

Investor Relations Contact:	Media Relations Contact:
Amy Greene +1 303-301-3313 [email protected]	Stacey Giglio +1 321-361-6101 [email protected]

                                

NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 65,886 restricted stock units of the company’s common stock to 39 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370